Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.

PIB: Quality control of Ayush drugs

Ensure time-bound Infrastructure development of Ayush National Institutes/Central Councils projects: Sonowal

Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.

Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review

The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

India has achieved replacement level fertility: Minister Pawar

Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.

Velocity Clinical Research begins European expansion with German site acquisition

Biopharma and CROs to benefit from simplified access to global research sites

Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate

This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.